Search Patents
  • CORONAVIRUS VACCINE AND METHODS OF USE THEREOF
    Publication number: 20210393769
    Abstract: An immunogenic composition effective for eliciting an immune response against cells that present coronavirus S protein and/or coronavirus M protein derived antigens on a virus-like-particle (VLP) system. In a method embodiment, the antigen presenting VLP is administered to a mammal, such as a human, to elicit an immune response against coronavirus S protein and/or coronavirus M protein. A preferred method embodiment may include at least one additional dose of immunogenic composition to enhance the immune response effectiveness of the coronavirus vaccine.
    Type: Application
    Filed: June 8, 2021
    Publication date: December 23, 2021
    Inventor: Davinder Gill
  • SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION
    Publication number: 20210322390
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: June 30, 2021
    Publication date: October 21, 2021
    Inventors: Dror Ben-Asher, Reza Fathi
  • BIOMARKERS OF CORONAVIRUS PNEUMONIA
    Publication number: 20230000845
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: August 31, 2022
    Publication date: January 5, 2023
    Inventors: Dror Ben-Asher, Reza Fathi, Mark Levitt, Ofra Barnett
  • METHOD FOR TREATMENT OF CORONAVIRUS INFECTION
    Publication number: 20210338708
    Abstract: The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.
    Type: Application
    Filed: March 18, 2021
    Publication date: November 4, 2021
    Inventors: Donald Jeffrey KEYSER, Alvaro F. GUILLEM, Bhupinder SINGH, Richard A. ZAGER, Stacey RUIZ
  • PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION
    Publication number: 20210261644
    Abstract: Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 26, 2021
    Inventors: Zhiwei Chen, Kwok Yung Yuen, Honglin Chen, Yik Chun Wong, Li Liu
  • METHOD FOR TREATING CORONAVIRUS INFECTIONS
    Publication number: 20210236497
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: April 16, 2020
    Publication date: August 5, 2021
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • CORONAVIRUS (COVID-19) AIR SANITIZATION/ISOLATION SYSTEM WITH ANTI-VIRUS CURTAIN WALLS
    Publication number: 20220040354
    Abstract: Various embodiments are directed to a coronavirus air sanitization/isolation system with anti-virus curtain. The system may include a group of anti-virus strips with attached separation magnets coupled to an air inlet housing mounted above (e.g., in an attic ceiling) in an enclosed space. The anti-virus strips may be coated with a saline and soap solution that attracts airborne droplets contaminated with the coronavirus and dissolves a fatty layer of coronavirus cell membranes to prevent cell replication of the coronavirus, thereby destroying the coronavirus. The air inlet housing may include exhaust ventilation fans, salt filters, a wick saturated with the saline and soap solution, an electro-static air filter, and a distribution air duct. The fans may be utilized to circulate an airstream containing the coronavirus through the anti-virus strips, the filters, the saturated wick, and the distribution air duct to remove the coronavirus while protecting occupants with uncontaminated air.
    Type: Application
    Filed: August 3, 2021
    Publication date: February 10, 2022
    Inventor: Charles Magee
  • CORONAVIRUS VACCINES COMPOSITIONS AND METHOD OF USING SAME
    Publication number: 20230117744
    Abstract: The present disclosure provides compositions, for example vaccine compositions comprising live, attenuated coronavirus. The disclosure also provides methods of using coronavirus vaccines, including methods of treating and/or preventing coronavirus infections, and provides methods of preparing coronavirus vaccines.
    Type: Application
    Filed: March 23, 2021
    Publication date: April 20, 2023
    Inventors: Susan Baker, Xufang Deng, Kelly Milton Lager, Kay Faaberg, Alexandra DeVries
  • SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION IN MODERATELY SEVERE PATIENTS WITH PNEUMONIA
    Publication number: 20220184053
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 16, 2022
    Inventors: Dror Ben-Asher, Reza Fathi
  • CORONAVIRUS VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO
    Publication number: 20230143228
    Abstract: This disclosure relates to methods of promoting immune responses against coronavirus, such as SARS-CoV-2, and compositions related thereto. In certain embodiments, this disclosure relates to methods of vaccinating for coronavirus comprising administering to the subject a composition disclosed herein. In certain embodiments, the composition comprises a recombinant virus such as recombinant MVA that encodes a coronavirus spike protein. In certain embodiments, the coronavirus spike protein comprises a proline mutation at position 986. In certain embodiments, the coronavirus spike protein comprises a proline mutation at position 987.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 11, 2023
    Inventors: Rama Rao AMARA, Sailaja GANGADHARA, Nanda Kishore ROUTHU
  • NOVEL COMPOSITIONS FOR TREATMENT OF CORONAVIRUS DISEASE
    Publication number: 20230110899
    Abstract: The present invention provides for use of fenretinide, fenretinide analog or pharmaceutically acceptable salts for the preparation of medicaments useful for the treatment of SARS-coronavirus, ARDS and SARS-coronavirus associated pneumonia and hypoxemia. In addition, prophylaxis of SARS-coronavirus, ARDS and SARS-coronavirus associated pneumonia is also contemplated.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 13, 2023
    Inventors: Radu Pislariu, Irenej Kianicka, Danuta Radzioch, Larry Lands
  • Sphingosine kinase 2 inhibitor for treating coronavirus infection
    Patent number: 11364227
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: June 21, 2022
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • Sphingosine kinase 2 inhibitor for treating coronavirus infection
    Patent number: 11052073
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: July 6, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • METHOD FOR TREATING CORONAVIRUS INFECTIONS
    Publication number: 20220378815
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: August 3, 2022
    Publication date: December 1, 2022
    Applicant: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION
    Publication number: 20210299108
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: June 10, 2021
    Publication date: September 30, 2021
    Inventors: Dror Ben-Asher, Reza Fathi
  • Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
    Publication number: 20050276818
    Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
    Type: Application
    Filed: May 17, 2005
    Publication date: December 15, 2005
    Inventors: Adam Godzik, Sergey Sikora
  • Serine protease inhibitor for treating coronavirus infection
    Patent number: 11045453
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: June 29, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
    Patent number: 11471448
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: October 18, 2022
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi, Mark Levitt, Ofra Barnett
  • Methods And Compositions For Treating Coronavirus
    Publication number: 20220088403
    Abstract: Disclosed are methods of inhibiting a coronavirus from infecting or replicating in a cell comprising exposing the cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, wherein the frequency and field strength of the alternating electric field inhibits coronavirus infection or replication. Disclosed are methods of reducing coronavirus copy number per cell comprising exposing the cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, wherein the frequency and field strength of the alternating electric field reduces coronavirus copy number in the cell. Disclosed are methods of treating a subject infected with coronavirus comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more coronavirus infected cells.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: Tali Voloshin-Sela, Lilach Avigdor, Yaara Porat, Moshe Giladi, Helena Are Yaara, Helena Mumblat
  • Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
    Patent number: 7504205
    Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: March 17, 2009
    Assignee: The Burnham Institute
    Inventors: Adam Godzik, Sergey Sikora
Narrow Results

Filter by US Classification